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It is known that irritable bowel syndrome (IBS) is a chronic disease of cyclic nature characterized by recurrent symptoms. IBS
patients should receive, as initial therapeutic approach a short course of treatment which, if eﬀective, has the additional value of
conﬁrming the diagnosis. Long-term treatment should be reserved to diagnosed IBS patients with recurrent symptoms. Clinical
trials with stabilized therapies and new active treatments showed an improvement of the symptoms over placebo that is often
time-dependent but with high relapse rates (around 40%–50% when stopping treatment). Relapse is not always immediate after
stopping treatment and the recent data from OBIS trial with otilonium bromide or with psychotherapy, showed that due to
diﬀerent chemico-physical characteristics of the drugs or the psychosomatic impact to the disease not all treatment gave the same
relapsing rate if compared to placebo. Results of IBS clinical trials with diﬀerent therapies tailored to the patient needs indicate
that a cyclic treatment therapy is advisable to counteract the nature of the disease.
1. NaturalHistory of IBS
Inordertodeterminewhethershort-orlong-termtreatment
is needed for irritable bowel syndrome (IBS), it is important
to know the natural history of this disease. Various studies
have looked at this. A Swedish group of researchers used a
validated questionnaire to assess the course of IBS in over
1,000 patients with symptomatic IBS at the index assessment
[1]. The questionnaire was administered again 1 and 7 years
later, and at both time-points more than 50% of the people
were still symptomatic with IBS (Figure 1). A further 25%
of the patients had minor IBS symptoms, and the remaining
had no longer symptoms. Similar results emerged from a
survey in Olmsted County in a population of 1365 humans
from which 166 were diagnosed as IBS patients [2]. In
this case the follow-up was 12 years but again just over a
quarter of the patients became symptom-free, whereas the
remaining still had IBS symptoms. An international study
f o l l o w e dc h a n g e si ns y m p t o m si nas h o r t e rt i m ef r a m e( 1 2
weeks; [3]). Patients used an interactive telephone data entry
system to report daily symptoms. The presence and duration
of individual symptoms and their concomitant occurrence
were determined on a total of 59 IBS patients. The main
symptoms, such as pain, bloating, and change in stool form,
were present in about 20% of the days. The mean duration
of the symptoms was about 5 days for pain and bloating
and between 1 and 2 days for the other symptoms. These
results were conﬁrmed in a large European study in which it
was found that IBS patients were symptomatic for about one
quarter of the days in a month [4]. Ford et al. [5]r e p o r t e d
that of the 1402 individuals symptomatic at baseline, 404
(29%) remained in the same subgroup at 10 years while a
large proportion of other patients changed subgroups alter-
ing their predominant symptoms and developing dyspepsia
or gastrooesophageal reﬂux diseases. Symptom stability was
more likely in males and older subjects.
Indeed, there is strong evidence that the pattern of IBS
symptoms is cyclical; more than half of IBS patients is still
symptomatic after up to 10 years, and symptoms wax and
wane within days to weeks [6].
2.Symptom CourseduringandRelapseRate
after 3 Months of Treatment
Although IBS is clearly a chronic disease, the initial thera-
peutic approach is to give a short course of treatment (often
3 months), which if eﬀective has the additional value of con-
ﬁrming the diagnosis. The symptom course during 3 months2 Gastroenterology Research and Practice
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Figure 1: Representative diagram of the stability over time of IBS:
percentage of the patients reporting IBS after 1 and 7 years from the
ﬁrst interview. Modiﬁed from [1].
of treatment and the relapse rate after such treatment have
been revealed by the results of several drug trials.
A recent phase II study performed with linaclotide, an
agonist of guanylate cyclase-C for the treatment of IBS
patients with constipation (C), showed that all the doses
utilised improved abdominal pain compared with placebo
along the improvement of other intestinal habits [12]. The
studywascarriedoutonatotalof420C-IBSandforaperiod
of 12 weeks. The symptoms were progressively improved
during the treatment time but their observation, 2 weeks
afterthetreatment,revealedthereturntobaselinelevels[12].
Lubiprostone, a prostaglandin E1 derivative that activates
epithelial chloride channels and approved by FDA on 2008,
has been tested in women with C-IBS. In one of the 3-
month phase III trial (n = 436; [13]) the eﬃcacy of this
new drug was demonstrated over placebo group but at the
conclusion of the 4-week randomised withdrawal period
conducted in overall responders, 38% of patients who were
randomised to continue lubiprostone and 40% of those who
were randomised to placebo were reported to be monthly
responders showing any diﬀerence between active treatment
and placebo in this period [14].
In another IBS trial, patients were treated with the spas-
molytic otilonium bromide or placebo for 4 months and the
main symptoms were recorded. Not surprisingly, there were
improvements in both groups, but the therapeutic gain (i.e.,
the diﬀerence between the improvements produced by otilo-
nium bromide and placebo) persisted each month of treat-
ment in terms of responder rate [15]. A similar schedule was
applied for another recent study, and the results obtained on
the eﬀect of otilonium on pain frequency and bloating were
found signiﬁcant, and these symptoms improved progres-
sively during the study [9]. This means that therapeutic gain
is not limited to the ﬁrst few weeks of treatment and it may
be worthwhile continuing treatment even if it is not immedi-
atelysuccessful.Ontheotherhand,IBStrialsaresubjectedto
high placebo eﬀect, typically between 30 and 60%, and this
makes diﬃcult to detect the therapeutic gain and interpreta-
tion of the results [7, 16, 17]. Two meta-analyses have shown
that stringent entry criteria and an increased number of
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Figure 2: Placebo response plotted against length of trial for 27
randomised controlled trials performed during 1976–1998. There
are not enough data points between 3–6 months, but it appears
that the placebo response increases and then decreases with time,
peaking at 8 weeks. Modiﬁed from [7].
oﬃce visits are factors able to decrease the placebo response
inaclinicaltrial[16,17].Beingthepsychosomaticpartofthe
IBS, an important side of the disease, the reassuration and
patient-practitioner relationship can give positive results. As
seeninFigure 2,whentheplaceboresponseisplottedagainst
the length of the study, a parabolic curve is drawn with the
maximum of placebo response at around 6–8 weeks and a
clear decline after approximately 12 weeks [7]. Therefore the
placebo-controlled trials in IBS shall be realised with a time
period of the active treatment superior to the 8 weeks as
stated since from Rome II criteria deﬁnition [18].
In another study, 623 patients were assigned to treatment
with alosetron, a 5HT-3 antagonist used for diarrhoea (D)
predominant IBS, or with the spasmolytic mebeverine for 3
months [19]. Symptoms recurred in both treatment groups,
during the 4-week follow-up period, with the relapse rate
being between 30–45%. The patients who did not relapse
in this period may have relapsed later or had a spontaneous
improvement, compatible with the above described natural
history of IBS. The relapse rate was also recorded in a Ger-
manstudyofpatientswithC-IBStreatedwith5-HT4agonist
tegaserod [20]. The study was carried out on more than 300
patients, and the primary eﬃcacy parameter was the week-
ly satisfactory relief of the symptoms over the past week. Pa-
tients who responded to a 3-month course of this drug were
taken oﬀ the medication and followed for 1 to 2 months.
If symptoms recurred, they were retreated [8]. During the
treatment period symptoms improved progressively. If treat-
ment was withdrawn, the symptoms recurred and if
treatment was restarted, the symptoms improved again
(Figure 3). The relapse rate in the ﬁrst month of treatment
withdrawal exceeded 50%. Unfortunately in this trial the
placebo response was not considered, and we cannot know
the real therapeutic gain obtained during the follow-up peri-
od.
In this regard new ﬁndings come from the above-cited
OBIS study of Clav` e et al. [9] with otilonium bromide. After
12 weeks of treatment, both patients treated with the active
treatment (n = 82) or those with placebo (n = 80) were
followedfor3,6,or10weeks.OnlysuccessfultreatedpatientsGastroenterology Research and Practice 3
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Figure 3: Mean abdominal pain/discomfort score (a) and bloating score (b) in patients cohort enrolled in retreatment phase with tegaserod.
Modiﬁed from [8].
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Figure 4: Percentage of the patients relapsing during the follow-
up treatment free-period (at 3, 6, and 10 weeks) after 12 weeks
treatment with placebo or otilonium bromide. ∗P<0.05 as
compared to respective placebo group. From OBIS trial [9].
were eligible for this follow-up period. The results indicate
the loss of therapeutic eﬀect of placebo and the persistence
of the eﬀect of otilonium bromide since the percentage of
relapsing patients at 3 and 6 weeks was signiﬁcantly higher in
the placebo group (Figure 4). Probably the chemicophysical
characteristics of this drug and its aﬃnity for colonic smooth
muscle [21] may be factors inﬂuencing the extension of the
beneﬁts due to the treatment that was not observed with
other drugs.
In summary, the therapeutic gain from active treatment
may extend beyond 4 weeks, but relapse rates are high
(around 40% when stopping treatment after 3 months);
relapse is not always immediate after stopping treatment.
3. Symptom Courseand Relapse Rateafter
One Year of Treatment
Other studies have determined the eﬀect of long-term treat-
ment on the symptom course and relapse rate of IBS. In
a continuation of the study with tegaserod above cited [8],
the therapeutic gain was maintained over the entire 1-year
period of active treatment in a total of 451 C-IBS patient
who completed the trial [22]. Another study using otilonium
bromide has prolonged the active treatment up to a period of
2y e a r s[ 10]. In this study otilonium was compared to ﬁber-
rich diet in 114 patients suﬀering from IBS. Both abdom-
inal pain and the intestinal function improved (Figure 5)
progressively during the study conﬁrming that the long-
term treatment is useful and particularly with the use of safe
drugs such as otilonium that thanks to its physico-chem-
ical characteristics cannot be absorbed by the systemic cir-
culation and act locally in the gut like the majority of4 Gastroenterology Research and Practice
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Figure 5: Eﬀect of long-term treatment with otilonium bromide on pain episodes (a) and bowel habits (b) reported by patients. Modiﬁed
from [10].
quaternary ammonium derivatives [21]. In another long-
term study with the use of alosetron, 714 women with severe
D-IBSweretreated[11].Randomisedpatientsreceivedeither
alosetron 1mg (n = 351) or placebo (n = 363) twice a day
during a 48-week double-blind study. The primary endpoint
was the 48-week average rate of adequate relief of IBS pain
and discomfort. Alosetron-treated patients had signiﬁcantly
greater adequate relief than placebo-treated patients (P<
0.05) in 9 of 12 months and signiﬁcantly greater urgency
control (P<0.001) every month (Figure 6). Placebo eﬀect
peaked after 1 month of treatment and was stable for the
other months at around 40%. It is noteworthy that when
treatment was stopped, relapse occurred in nearly half of the
patients after 1 month of observation.
The beneﬁt of active treatment can be maintained for
up to 1 year or more, but the relapse rate after treatment
withdrawal following long-term therapy (1-year) is still high,
being around 40%.
4.Symptom Courseduringand
after Psychotherapy
Interestingly, the symptom course and relapse pattern after
psychotherapy seem to diﬀer from those after drug treat-
ment.Inonetrial,101IBSpatientsreceivedstandardmedical
therapy with or without psychotherapy administered over
a 3-month period [23]. During the 3-month intervention
period, the improvement was greater in the psychotherapy
group than that in the control group. Subsequently, in
a 1-year treatment-free followup, the improvement contin-
uedinthepsychotherapygroup,whereassymptomsrecurred
in the controls, returning to their initial state.
5. Approachto the Patient
ThetypeofIBStreatmentmustbetailoredtopatients’needs.
Some patients require only “single-shot” treatment. They
have symptoms for 1 or 2 days and do not need an entire
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Figure 6: Eﬀect of 1-year treatment with alosetron or placebo
and percentage of patients with adequate relief after 1 month of
followup. ∗P<0.05 as compared to respective placebo group.
Modiﬁed from [11].
treatment course. Others have symptoms for a couple of
days or weeks and need a course of treatment. Yet others
have more or less continuous symptoms and need long-
term treatment. Not all types of treatments are suitable for
all applications. Spasmolytics, laxatives, and loperamide are
suited for all three types of treatment: single-shot treat-
ment, a limited course of treatment, and a long-term treat-
ment. Prokinetics, on the other hand, are not suitable for
“single-shot” treatment—they need some days to work.
Antidepressants must be given for some months or even
years with a look to their potential side eﬀects. Finally, psy-
chotherapy is administered over a couple of weeks, but it is
not usually continued for months or years.
6. Short- and Long-Term
Treatment: Advantages
There are advantages of both short-term and long-term
treatment. The arguments in favour of long-term treatment
are that more than half of IBS patients continue to haveGastroenterology Research and Practice 5
symptoms over many years, and the therapeutic gain of a
pharmacological treatment continues for weeks or months.
The relapse rate after stopping treatment is high (around
50%). Furthermore, some treatments require quite a long
time to work. The arguments in favour of a short-term treat-
ment are that about half of the patients improve over time
and do not, therefore, need prolonged treatment. Although
therelapserateaftertreatmentsuspensionishigh,about50%
of patients do not relapse and most relapses do not occur
immediately, a treatment-free interval can be gained. Some
treatments, such as psychotherapy, can have long-lasting
eﬀects.Thediﬀerentdimensionsofsymptoms(intensity,fre-
quency, and speciﬁcity) in a given patient also determine
the best therapeutic approach. For example, a symptom may
be of mild, moderate, or severe intensity, requiring only re-
assurance in some patients, an intervention in others, or in
the most severe cases, multimodal intervention. Likewise,
occasional, intermittent, or continuous symptoms will dic-
tatewhetheron-demand treatment,alimited courseof treat-
ment or continuous treatment is necessary. The speciﬁc
symptom will govern the choice of the appropriate drug.
In conclusion, the drug of ﬁrst choice is selected based on
the dominant symptom. If this treatment is unsuccessful, the
drug can be changed. If the treatment is successful, it can be
suspended after a limited course. If a relapse occurs, treat-
ment should be resumed with the same drug. If, however,
the patient remains in remission he or she will not receive
unnecessary treatment.
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